Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

ion of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... (Nasdaq: SLTM ), a global leader in the ... the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton ... pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief ... corporate events. Attendance at this conference is by ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) ... medical devices to biopharmaceutical and healthcare organizations and ... efficacy services in drug development, announced today results ...  Unless otherwise noted, all comparative numbers refer to ...
Cached Medicine Technology:Solta Medical to Present at the JMP Securities Research Conference 2ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11
(Date:4/24/2014)... BrainHealth will bring together national experts to discuss ... its inaugural Brain Health Summit, titled "The Human ... include Dr. Sandra Bond Chapman, founder and chief ... Chuck Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) ... and Early Learning, U.S. Department of Education. The ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... CORVALLIS, Ore. An Oregon State University researcher has ... severity of the symptoms of autism spectrum disorder in ... the be the first to show a direct relationship ... of fine and gross motor skills should be included ... Megan MacDonald, an assistant professor in OSU,s College of ...
(Date:4/24/2014)... a scientist at the University of York reveals that ... development of the nervous system may also play a ... A research team, led by Dr Will Brackenbury, a ... at York, has studied how voltage-gated sodium channels assist ... found in the membranes of excitable cells, such as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... , , ... Corp., the leader in clinically proven brain fitness software, and ... collaboration to empower individuals with knowledge and tools that can ... this first-of-its-kind offer, consumers will have the opportunity to complement ...
... , , HOUSTON, Sept. ... that Dan Moore, President and Chief Executive Officer, and Greg Browne, ... Conference in New York on Tuesday, September 22, 2009 at 4:00 ... live and by replay at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=82_IT8KY1C . ...
... , PORTLAND, Maine, Sept. 10 ... Council for Disability Awareness (CDA) reveals a surge in the number ... , , The CDA,s 4(th) Annual Long-Term Disability ... identifies continuing and emerging disability trends among U.S. workers. Fifteen CDA ...
... STERIS Corporation (NYSE: STE ) today announced that the ... in New York on Tuesday, September 22, 2009. Michael J. ... p.m., Eastern time. , , The presentation can ... at www.steris-ir.com . The presentation will be ...
... ... Pioneer in the Development of Telehealth-Supported Solutions for Connected Care , ... Minneapolis, MN (PRWEB) September 10, 2009 ... Lenzmeier as chairman. Founded in 1993, ATI is the pioneer in the development and ...
... , , ANN ... biopharmaceutical company, today announced positive efficacy results from the second ... study for Ophena(TM) (ospemifene tablets), the company,s investigational ... (VVA). This study, together with the recent completion of ...
Cached Medicine News:Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 2Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 3Health News:Cyberonics to Present at UBS Global Life Sciences Conference 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 3Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 2Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 3Health News:Allen Lenzmeier Elected Chairman of the Board of Directors of American TeleCare, Inc. (ATI) 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 3Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: